Table 1 Baseline characteristics of the study population
Variable | TBI/Cy (n = 78) | Bu/Cy (n = 41) | p value |
|---|---|---|---|
*Age (years) | 27.64 ± 7.67 (19–49) | 27.46 ± 7.00 (19–41) | 0.902 |
Recipient sex | |||
Males Females | 56 (71.8) 22(28.2) | 30 (73.2) 11(26.8) | 0.873 |
Immunophenotype | |||
B T | 52 (66.7) 26 (33.3) | 27 (65.9) 14 (34.1) | 0.929 |
Performance status | |||
0–1 2 | 75 (96.2) 3 (3.8) | 38 (92.7) 3 (7.3) | 0.339 |
Ph chromosome status | |||
Negative Positive | 60 (76.9) 18 (23.1) | 32 (78) 9 (22) | 0.889 |
Disease status at transplant | |||
CR 1 ≥ CR 2 | 40 (51.3) 38 (48.6) | 16 (39) 25 (61) | 0.203 |
Pre-transplant Comorbidities | |||
No Yes | 76 (85.9) 11 (14.1) | 37 (90.2) 3 (9.8) | 0.497 |
Donor sex | |||
Females Males | 33 (42.3) 45 (57.7) | 22 (53.7) 19 (64.3) | 0.238 |
Donor/recipient CMV seropositivity | |||
Mismatched Matched | 7 (9) 71 (91) | 2 (4.9) 39 (95.1) | 0.717 |
*Diagnosis to transplant lag period (month) | 16.25 (14–137.3) | 13.5 (4.9–73.2) | 0.114 |